Vivimed Labs Ltd. (NSE: VIVIMEDLAB, BSE: 532660) is a Hyderabad, Telangana-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹45 Cr, it ranks #3,859 by market cap among the 6,197 Indian listed companies on FinBizNet, and #21 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹5.20 (as of 16 Nov 2026), the share price is 80.5% below its 52-week high of ₹26.60 and 9.5% above its 52-week low of ₹4.75. The share price is up 5.1% over one year and up 4.8% over three months.
| Current Price | ₹5.20 |
|---|---|
| Market Cap | ₹45 Cr |
| NSE Symbol | VIVIMEDLAB |
| BSE Code | 532660 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Assets | -12.85% |
| 52-Week Range | ₹4.75 – ₹26.60 |
| 1-Year Price Change | +5.1% |
| 3-Month Price Change | +4.8% |
| Beta (1Y) | -0.98 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.vivimedlabs.com |
| Revenue | ₹12 Cr |
|---|---|
| Net Profit | ₹-146 Cr |
| Net Margin | -1216.9% |
| EPS (Basic) | ₹-17.74 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vivimed Labs Ltd. reported revenue of ₹12 Cr in Q4 FY26, down 53.1% from ₹26 Cr in Q4 FY25 and down 25.0% from ₹16 Cr in Q3 FY26. It posted a net loss of ₹146 Cr for the quarter, against a net loss of ₹5 Cr in Q4 FY25. Across the 5 quarters from Q4 FY25 to Q4 FY26, quarterly revenue ranged from ₹12 Cr (Q4 FY26) to ₹26 Cr (Q4 FY25). The company reported a net loss in 5 of these 5 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q4 FY26 | ₹12 Cr | −₹146 Cr | −1216.9% |
| Q3 FY26 | ₹16 Cr | −₹17 Cr | −103.5% |
| Q2 FY26 | ₹21 Cr | −₹7 Cr | −35.4% |
| Q1 FY26 | ₹21 Cr | −₹5 Cr | −25.7% |
| Q4 FY25 | ₹26 Cr | −₹5 Cr | −20.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 7.57% of Vivimed Labs Ltd.'s shares as of Mar 2026, against 20.94% in Mar 2025 (−13.37 percentage points).
Vivimed Labs Ltd. made 6 exchange disclosures in the Corporate Insolvency Resolution Process (CIRP) category between 13 Feb 2026 and 8 Sept 2026. The filings do not mention a Committee of Creditors or a Resolution Professional. Disclosures in this category can concern a petition, an appeal, a subsidiary or another company.
Taken from the company's own stock exchange filings. FinBizNet does not infer the current status of any proceeding.
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also exports its products. The company was incorporated in 1988 and is based in Hyderabad, India.
1. Speciality Chemicals Business-This segment manufactures specialty chemicals. 2. Pharma Business-This segment offers active pharmaceuticals ingredients. It also provides finished dosage formulation contract development and manufacturing services. 3. Segment Adjustment-NA 4. Corporate-NA
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Vivimed Labs Ltd. | ₹45 Cr | n/m | — | ₹12 Cr | +5.1% |
Listed by market capitalisation. Ratios are shown for context only.
Vivimed Labs Ltd. is trading at ₹5.20, with a market capitalisation of ₹45 Cr.
Vivimed Labs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Vivimed Labs Ltd. is listed on the NSE under the symbol VIVIMEDLAB and on the BSE under the scrip code 532660.
Vivimed Labs Ltd.'s share price is up 5.1% over one year and up 4.8% over three months. Its 52-week range is ₹4.75 to ₹26.60.
In Q4 FY26, Vivimed Labs Ltd. reported revenue of ₹12 Cr and net profit of ₹-146 Cr, with basic EPS of ₹-17.74 (consolidated, parsed from the company's exchange filing).
Vivimed Labs Ltd. reported revenue of ₹12 Cr in Q4 FY26, down 53.1% from ₹26 Cr in Q4 FY25 and down 25.0% from ₹16 Cr in Q3 FY26.
Promoters held 7.57% of Vivimed Labs Ltd.'s shares as of Mar 2026, against 20.94% in Mar 2025 (−13.37 percentage points).
Vivimed Labs Ltd. made 6 exchange disclosures in the Corporate Insolvency Resolution Process (CIRP) category between 13 Feb 2026 and 8 Sept 2026. The filings do not mention a Committee of Creditors or a Resolution Professional. Disclosures in this category can concern a petition, an appeal, a subsidiary or another company.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.